Human mismatch repair, drug-induced DNA damage, and secondary cancer

Biochimie

Volumn 85, Issue 11, 2003, Pages 1149-1160

  Karran, Peter ^a   Offman, Judith ^a   Bignami, Margherita ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; DNA damage; MMR

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CARBAMAZEPINE; CHLOROQUINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIGOXIN; DIURETIC AGENT; DNA; ENALAPRIL; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; MERCAPTOPURINE; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PENICILLAMINE; PHENYLBUTAZONE; PHENYTOIN; PREDNISONE; SALICYLATE SODIUM; SALICYLIC ACID; STEROID; THYMOCYTE ANTIBODY; UNINDEXED DRUG; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENICITY; CELL DEATH; CHEMICAL CARCINOGENESIS; CHEMICAL MUTAGENESIS; COLITIS; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DNA METHYLATION; DNA REPLICATION; DRUG INDUCED CANCER; ENDOMETRIUM CANCER; ERROR; FAMILIAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENOTOXICITY; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETHALITY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; TRANSPLANTATION;

EID: 0942289903     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biochi.2003.10.007     Document Type: Article

References (98)

1. Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 21:2003;1174-1179.
2. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA. 95:1998;6870-6875.
3. Young J., Simms L.A., Biden K.G., Wynter C., Whitehall V., Karamatic R., George J., Goldblatt J., Walpole I., Robin S.A., Borten M.M., Stitz R., Searle J., McKeone D., Fraser L., Purdie D.R., Podger K., Price R., Buttenshaw R., Walsh M.D., Barker M., Leggett B.A., Jass J.R. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am. J. Pathol. 159:2001;2107-2116.
4. Karran P., Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 16:1994;833-839.
5. Aquilina G., Bignami M. Mismatch repair in correction of replication errors and processing of DNA damage. J. Cell. Physiol. 187:2001;145-154.
6. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res. 61:2001;7369-7374.
7. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica. 84:1999;937-945.
8. Casorelli I., Offman J., Mele L., Pagano L., D'Errico M., Sica S., Giannini G., Leone G., Bignami M., Karran P. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair. 2:2003;547-559.
9. Duckett D.R., Bronstein S.M., Taya Y., Modrich P. hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage. Proc. Natl. Acad. Sci. USA. 96:1999;12384-12388.
10. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA. 93:1996;6443-6447.
11. 6-methylguanine and 6-thioguanine cytotoxic effects: a cross-resistant phenotype in N-methylnitrosourea-resistant Chinese hamster ovary cells. Cancer Res. 50:1990;4248-4253.
12. 2 cell cycle checkpoint. Cancer Res. 55:1995;3721-3725.
13. Swann P.F., Waters T.R., Moulton D.C., Xu Y.-Z., Edwards M., Mace R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 273:1996;1109-1111.
14. 6-methylthioguanine. Biochemistry. 36:1997;2501-2506.
15. Zhukovskaya N., Branch P., Aquilina G., Karran P. DNA replication arrest and tolerance to DNA methylation damage. Carcinogenesis. 15:1994;2189-2194.
16. Maybaum J., Mandel H.G. Unilateral chromatid damage: a new basis for 6-thioguanine cytotoxicity. Cancer Res. 43:1983;3852-3856.
17. Dosch J., Christmann M., Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis. 19:1998;567-573.
18. Mazurek A., Berardini M., Fishel R. Activation of human MutS homologs by 8-oxo-guanine DNA damage. J. Biol. Chem. 277:2002;8260-8266.
19. Mu D., Tursun M., Duckett D.R., Drummond J.T., Modrich P., Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol. Cell. Biol. 17:1997;760-769.
20. Yamada M., O'Regan E., Brown R., Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res. 25:1997;491-495.
21. Li G.-M., Wang H., Romano L.J. Human MutSa specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts. J. Biol. Chem. 271:1996;24084-24088.
22. Wu J., Gu L., Wang H., Geacintov N.E., Li G.-M. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol. Cell. Biol. 19:1999;8292-8301.
23. DeWeese T.L., Shipman J.M., Larrier N.A., Buckley N.M., Kidd L.R., Groopman J.D., Cutler R.G., Riele H.T., Nelson W.G. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc. Natl. Acad. Sci. USA. 95:1998;11915-11920.
24. Colussi C., Parlanti E., Degan P., Aquilina G., Barnes D., Macpherson P., Karran P., Crescenzi M., Dogliotti E., Bignami M. The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidised dNTP pool. Curr. Biol. 12:2002;912-918.
25. Lin X., Ramamurthi K., Mishima M., Kondo A., Howell S.B. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Mol. Pharmacol. 58:2000;1222-1229.
26. Gasche C., Chang C.L., Rhees J., Goel A., Boland C.R. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res. 61:2001;7444-7448.
27. Nara K., Nagashima F., Yasui A. Highly elevated ultraviolet-induced mutation frequency in isolated Chinese hamster cell lines defective in nucleotide excision repair and mismatch repair proteins. Cancer Res. 61:2001;50-52.
28. Claij N., van der Wal A., Dekker M., Jansen L., Riele H.T. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis. Cancer Res. 63:2003;2062-2066.
29. Aebi S., Fink D., Gordon R., Kim H.K., Fink J.L., Howell S.B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 3:1997;1763-1767.
30. Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumour cells. Oncogene. 19:2000;3138-3145.
31. Lin X., Howell S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol. 56:1999;390-395.
32. Duc R., Leong-Morgenthaler P.M. Heterocyclic amine induced apoptotic response in the human lymphoblastoid cell line TK6 is linked to mismatch repair status. Mutat. Res. 486:2001;155-164.
33. Zhang S., Lloyd R., Bowden G., Glickman B.W., de Boer J.G. Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methy1-6- phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon. Oncogene. 20:2001;6066-6072.
34. Giraud A., Matic I., Tenaillon O., Clara A., Radman M., Fons M., Taddei F. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science. 291:2001;2606-2608.
35. Kim H., Jen J., Vogelstein B., Hamilton S.R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am. J. Pathol. 145:1994;148-156.
36. Salovaara R., Loukola A., Kristo P., Kaariainen H., Ahtola H., Eskelinen M., Harkonen N., Julkunen R., Kangas E., Ojala S., Tulikoura J., Valkamo E., Jarvinen H., Mecklin J.-P., Aaltonen L.A., de la Chapelle A. Population-based molecular detection of hereditary non-poyposis colorectal cancer. J. Clin. Oncol. 18:2000;2193-2200.
37. Euvrard S., Kanitakis J., Claudy A. Skin cancers after organ transplantation. New Engl. J. Med. 348:2003;1681-1691.
38. Bignami M., Casorelli I., Karran P. Mismatch repair and response to DNA-damaging antitumor therapies. Eur. J. Cancer. 39:2003;2142-2149.
39. Reese J.S., Liu L., Gerson S.L. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood. 102:2003;1626-1633.
40. Pagano L., Pulsoni A., Tosti M.E., Annino L., Mele A., Camera A., Martino B., Guglielmi C., Cerri R., Bona E.D., Invernizzi R., Castagnola C., Bassan R., Mele L., Todeschini G., Leone G., Mandelli F. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Br. J. Haematol. 106:1999;1037-1040.
41. Allay J.A., Koc O.N., Davis B.M., Gerson S.L. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin. Cancer Res. 2:1996.
42. Worrilow L.J., Travis L.B., Smith A.G., Rollinson S., Smith A.J., Wild C.P., Holowaty E.J., Kohler B.A., Wiklund T., Pukkala E., Roman E., Morgan G.J., Allan J.M. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin. Cancer Res. 9:2003;3012-3020.
43. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 34:1993;1081-1085.
44. Cummins D., Sekar M., Halil O., Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation. 61:1996;1661-1662.
45. Thomsen J.B., Schroder H., Kristinson J., Madsen B., Szumlanski C., Weinshilboum H., Andersen J.B., Schmiegelow K. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 86:1999;1080-1086.
46. Block A.W., Carroll A.J., Hagemeijer A., Michaux L., Lom K.V., Olney M.J., Baer M.R. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 33:2002;401-412.
47. Mauritzson M., Albin M., Rylander L., Billstrom R., Ahlgren T., Mikoczy Z., Bjork J., Stromberg U., Nilsson P.G., Mitelman F., Hagmar L., Johansson B. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 16:2002;2366-2378.
48. Qin X., Liu L., Gerson S.L. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. Oncogene. 18:1999;4394-4400.
49. -/- mice. J. Natl. Cancer Inst. 93:2001;1534-1540.
50. Yoshino M., Nakatsu Y., Riele H.T., Hirota S., Kitamura Y., Tanaka K. Additive roles of XPA and MSH2 genes in UVB-induced skin tumorigenesis in mice. DNA Repair. 1:2002;935-940.
51. Meira L.B., Cheo D.L., Reis A.M., Claij N., Burns D.K., Riele H.T., Friedberg E.C. Mice defective in the mismatch repair gene Msh2 show increased predisposition to UVB radiation-induced skin cancer. DNA Repair. 1:2002;929-934.
52. Kohonen-Corish M.R.J., Daniel J.J., Riele H.T., Buffington G.D., Dahlstrom J.E. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumours. Cancer Res. 62:2002;2092-2097.
53. + tumour cells. Cell. 75:1993;1227-1236.
54. Tomlinson I.P.M., Hampson R., Karran P., Bodmer W.F. DNA mismatch repair in lymphoblastoid cells from HNPCC patients is normal under conditions of rapid cell division and increased mutational load. Mutat. Res. 383:1997;177-182.
55. Lindor N.M., Jalad S.M., VanDeWalker T.J., Cunningham J.M., Dahl R.J., Thibodeau S.N. Search for chromosome instability in lymphocytes with germ-line mutations in DNA mismatch repair genes. Cancer Genet. Cytogenet. 104:1998;48-51.
56. +/- lymphoblastoid cells to the methylating agent temozolomide. Proc. Natl. Acad. Sci. USA. 98:2001;7164-7169.
57. Lettieri T., Marra G., Aquilina G., Bignami M., Palombo F., Jiricny J. Effect of hMSH6 cDNA expression on the phenotype of mismatch repair-deficient colon cancer cell line HCT15. Carcinogenesis. 20:1999;373-382.
58. 2/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J. 22:2003;2245-2254.
59. de Wind N., Dekker M., Berns A., Radman M., Riele H.T. Inactivation of the mouse Msh2 gene results in postreplicational mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to tumorigenesis. Cell. 82:1995;321-330.
60. Bouffler S.D., Holland N., Cox R., Fodde R. Evidence for Msh2 haploinsufficiency in mice revealed by MNU-induced sister chromatid exchange analysis. Br. J. Cancer. 83:2000;1291-1294.
61. Claij N., Riele H.T. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level. Oncogene. 21:2002;2873-2879.
62. de Wind N., Dekker M., van Rossum A., van der Valk M., Riele H.T. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res. 58:1998;248-255.
63. Kawate H., Itoh R., Sakumi K., Nakabeppu Y., Tsuzuki T., Ide F., Ishikawa T., Noda T., Nawata H., Sekiguchi M. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of a alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis. 21:2000;301-305.
64. Qin X., Shibata D., Gerson S.L. Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumour induction with N-methyl-N-nitrosourea. Carcinogenesis. 21:2000;833-838.
65. Humbert O., Fiumicino S., Aquilina G., Branch P., Oda S., Zijno A., Karran P., Bignami M. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis. 20:1999;205-214.
66. Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., Ruano E., Puisieux A. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 59:1999;294-297.
67. Ricciardone M.D., Ozcelik T., Cevher B., Ozdag H., Tuncer M., Gurgey A., Uzunallimoglu O., Cetinkaya H., Tanyeli A., Erken E., Ozturk M. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 59:1999;290-293.
68. Whiteside D., McLeod R., Graham G., Steckly J.L., Booth K., Somerville M.J., Andrew S.E. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple cafe-au-lait spots. Cancer Res. 62:2002;359-362.
69. Olipitz W., Hopfinger G., Aguiar R.C.T., Gunsilius E., Girschikofsky M., Bodner C., Hiden K., Linkesch W., Hoefler G., Sill H. Defective DNA mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer. 34:2002;243-248.
70. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D., Zelig O., Yahalom V., Paltiel O., Peretz T., Ben-Neriah S., Yehuda O., Rachmilewitz E.A. Microsatellite instability and p53 mutations in therapy-related leukemia suggest a mutator phenotype. Blood. 88:1996;4296-4303.
71. Boyer J.C., Risinger J.I., Faber R.A. Stability of microsatellites in myeloid neoplasias. Cancer Genet. Cytogenet. 106:1998;54-61.
72. Horiike S., Misawa S., Kaneko H., Sasai Y., Kobayashi M., Fujii H., Tanaka S., Yagita M., Abe T., Kashima K., Taniwaki M. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia. 13:1999;1235-1242.
73. Das-Gupta E.P., Seedhouse C.H., Russell N.H. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br. J. Haematol. 114:2001;307-321.
74. Sheikhha M.H., Tobal K., Yin J.A.L. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 117:2002;359-365.
75. Olipitz W., Tilz G.P., Beham-Schmid C., Eibinger C., Kerzina P., Sill H. Microsatellite analysis in acute myeloid leukemia evolving from myelodysplastic syndrome. Br. J. Haematol. 112:2001;248-253.
76. Sill H., Goldman J.M., Cross N.C. Cross, Rarity of microsatellite alterations in acute myeloid leukaemia. Br. J. Cancer. 74:1996;255-257.
77. Ohyashiki K., Aizawa S., Kawakubo K., Shimamoto T., Iwama H., Hayashi S., Toyama K. Replication errors in hematological neoplasias: Genomic instability in progression of disease is different among different types of leukemia. Clin. Cancer Res. 2:1996;1583-1589.
78. Indraccolo S., Minuzzo S., Nicoletti L., Cretella E., Simon M., Papakonstantinou G., Hehlmann R., Mion M., Bertorelle R., Roganovic J., Chieco-Bianchi L. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements. Blood. 94:1999;2424-2432.
79. Rimsza L.M., Kopecky K.J., Ruschulte J., Chen J.-M., Slovak M.L., Karanes C., Godwin J., List A., Willman C.L. Microsatellite instability is not a genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature. Leukemia. 14:2000;1044-1051.
80. Ribeiro E.M.S.F., Rodriguez J.M., Coser V.M., Sotero M.G., Fonseca Neto J.M., Pasquini R., Cavalli I.J. Microsatellite instability and cytogenetic survey in myeloid leukemias. Brazil. J. Med. Biol. Res. 35:2002;153-159.
81. Maldonado N., Torres V.M., Mendez-Cashion D., Perez-Santiago E., Caceres de Costas M. Pyroderma gangrenosum treated with 6-mercaptopurine and followed by acute leukaemia. J. Pediatrics. 72:1968;409-414.
82. Cobau C.D., Sheon R.P., Kirsner A.B. Immunosuppressive drugs and acute leukaemia. Ann. Intern. Med. 79:1973;131-132.
83. Silvergleid A.J., Schrier S.L. Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases. Am. J. Med. 57:1974;885-888.
84. Roberts M.M., Bell R. Acute leukaemia after immunosuppressive therapy. The Lancet. 1976;768-770.
85. Seidenfeld A.M., Smythe H.A., Ogyzlo M.A., Urowitz M.B., Dotten D.A. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J. Rheumatol. 3:1976;295-304.
86. Gilmore I.T., Holden G., Rodan K.S. Acute leukaemia during azathioprine therapy. Postgrad. Medical J. 53:1977;173-174.
87. Alexon E., Brandt K.D. Acute leukemia after azathioprine treatment of connective tissue disease. Am. J. Med. Sci. 273:1977;355-440.
88. Vismans J.J., Briet E., Meijer K., den Ottolander G.J. Azathioprine and subacute myelomonocytic leukemia. Acta Med. Scand. 207:1980;315-319.
89. Pikler G.M., Say B., Stamper S. Cytogenetic finding in acute monocytic leukemia in a renal allograft recipient. Cancer Genet. Cytogenet. 20:1986;101-107.
90. Matteson E.L., Hickey A.R., Maguire L., Tilson H.H., Urowitz M.B. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J. Rheumatol. 18:1991;809-814.
91. Vasquez S., Kavanaugh A.F., Schneider N.R., Wacholtz M.C., Lipsky P.E. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J. Rheumatol. 19:1992;1625-1627.
92. Krishnan K., Adams P., Silveira S., Sheldon S., Dabich L. Therapy-related acute myeloid leukaemia following immunosuppression with azathioprine for polymyositis. Clin. Lab. Haematol. 16:1994;285-289.
93. Dombret H., Maroleau J.P. De novo acute myeloid leukemia in patients with Crohn's disease. Nouvelle Revue Francaise Hematologie. 37:1995;193-196.
94. Heizer W.D., Peterson J.L. Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine. Digestive Diseases and Sciences. 43:1998;1791-1793.
95. Kwong Y.L., Au W.Y., Liang R.H.S. Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genet. Cytogenet. 103:1998;94-97.
96. Arnold J.A., Ranson S.A., Abdalla S.H. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin. Lab. Haematol. 21:1999;289-292.
97. Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J. Rheumatol. 26:1999;1705-1714.
98. Heesen C., Bruegmann M., Gbdamosi J., Koch E., Moench A., Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Multiple Sclerosis. 9:2003;213-214.